{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:39:37Z","timestamp":1792111177594,"version":"4.4.0"},"reference-count":51,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The immune response to infused factor concentrates remains a major source of morbidity and mortality in the treatment of patients with hemophilia A and B. This review focuses on current treatment options and novel therapies currently in clinical trials. After a brief review of immune tolerance regimens, the focus of the discussion is on preventing bleeding in patients with hemophilia and inhibitors. Recombinant factor VIIa and activated prothrombin complex concentrates are the mainstays in treating bleeds in patients with inhibitors. Both agents have been shown to reduce bleeding episodes to a similar degree when infused prophylactically; however, individual patients may respond better to one agent over the other at any given time. The international immune tolerance trial revealed that a high-dose factor VIII regimen provided significantly better bleeding protection than the low-dose regimen. Given the high cost of treatment and the potential for a high-dose immune tolerance regimen to prevent bleeding in some patients, we discuss how we treat patients to maximize the prevention of bleeds while minimizing cost. Novel approaches to treatment of these patients are in development. These include agents that mimic factor VIII or augment thrombin generation by bypassing the inhibitor, as well as agents that inhibit the natural anticoagulants.<\/jats:p>","DOI":"10.1182\/asheducation-2016.1.657","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T16:05:27Z","timestamp":1480694727000},"page":"657-662","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":95,"title":["Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches"],"prefix":"10.1182","volume":"2016","author":[{"given":"Shannon L.","family":"Meeks","sequence":"first","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glaivy","family":"Batsuli","sequence":"additional","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111703153801700_B1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1046\/j.1365-2516.2002.00626.x","article-title":"Inhibitors: resolving diagnostic and therapeutic dilemmas","volume":"8","author":"Dimichele","year":"2002","journal-title":"Haemophilia"},{"issue":"3","key":"2019111703153801700_B2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2141.2007.06657.x","article-title":"Inhibitor development in haemophilia B: an orphan disease in need of attention","volume":"138","author":"DiMichele","year":"2007","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111703153801700_B3","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood-2013-02-483263","article-title":"Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A","volume":"122","author":"Eckhardt","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2019111703153801700_B4","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/pbc.24856","article-title":"Increased burden on caregivers of having a child with haemophilia complicated by inhibitors","volume":"61","author":"Lindvall","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2019111703153801700_B5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1365-2516.2011.02692.x","article-title":"Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008","volume":"18","author":"Guh","year":"2012","journal-title":"Haemophilia"},{"issue":"9","key":"2019111703153801700_B6","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1111\/j.1538-7836.2009.03538.x","article-title":"The molecular mechanisms of immunomodulation and tolerance induction to factor VIII","volume":"7","author":"Waters","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"23","key":"2019111703153801700_B7","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood-2014-05-577643","article-title":"Toward optimal therapy for inhibitors in hemophilia","volume":"124","author":"Kempton","year":"2014","journal-title":"Blood"},{"key":"2019111703153801700_B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2516.2007.01497.x","article-title":"International workshop on immune tolerance induction: consensus recommendations","volume":"13","author":"DiMichele","year":"2007","journal-title":"Haemophilia"},{"issue":"1","key":"2019111703153801700_B9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0037-1612943","article-title":"The North American Immune Tolerance Registry: practices, outcomes, outcome predictors","volume":"87","author":"DiMichele","year":"2002","journal-title":"Thromb Haemost"},{"issue":"6","key":"2019111703153801700_B10","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"The principal results of the International Immune Tolerance Study: a randomized dose comparison","volume":"119","author":"Hay","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2019111703153801700_B11","first-page":"1186","article-title":"Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success","volume":"86","author":"Mariani","year":"2001","journal-title":"Haematologica"},{"issue":"7","key":"2019111703153801700_B12","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1055\/s-0033-1356574","article-title":"Challenges in the management of hemophilia B with inhibitor","volume":"39","author":"Batorova","year":"2013","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"2019111703153801700_B13","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1365-2516.2003.00772.x","article-title":"Management of haemophilia B inhibitor patients with anaphylactic reactions to FIX concentrates","volume":"9","author":"Shibata","year":"2003","journal-title":"Haemophilia"},{"key":"2019111703153801700_B14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13052-015-0116-8","article-title":"Desensitization and immune tolerance induction in children with severe factor IX deficiency; inhibitors and adverse reactions to replacement therapy: a case-report and literature review","volume":"41","author":"Bon","year":"2015","journal-title":"Ital J Pediatr"},{"issue":"3","key":"2019111703153801700_B15","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/hae.12077","article-title":"Late immune tolerance induction in haemophilia A patients","volume":"19","author":"Meeks","year":"2013","journal-title":"Haemophilia"},{"issue":"5","key":"2019111703153801700_B16","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/hae.12730","article-title":"US Guidelines for immune tolerance induction in patients with haemophilia A and inhibitors","volume":"21","author":"Valentino","year":"2015","journal-title":"Haemophilia"},{"key":"2019111703153801700_B17"},{"issue":"6","key":"2019111703153801700_B18","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1538-7836.2004.00759.x","article-title":"Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors","volume":"2","author":"Abshire","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019111703153801700_B19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1046\/j.1365-2516.2002.00532.x","article-title":"Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events","volume":"8","author":"Ehrlich","year":"2002","journal-title":"Haemophilia"},{"issue":"5","key":"2019111703153801700_B20","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1365-2516.2008.01829.x","article-title":"Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors","volume":"14","author":"Abshire","year":"2008","journal-title":"Haemophilia"},{"issue":"2","key":"2019111703153801700_B21","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2006-04-017988","article-title":"A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study","volume":"109","author":"Astermark","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2019111703153801700_B22","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1365-2516.2009.02116.x","article-title":"Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series","volume":"16","author":"Ettingshausen","year":"2010","journal-title":"Haemophilia"},{"issue":"6","key":"2019111703153801700_B23","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"issue":"18","key":"2019111703153801700_B24","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1056\/NEJMoa1104435","article-title":"Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors","volume":"365","author":"Leissinger","year":"2011","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111703153801700_B25","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1111\/j.1538-7836.2007.02663.x","article-title":"Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors","volume":"5","author":"Konkle","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2019111703153801700_B26","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2516.2008.01654.x","article-title":"Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors","volume":"14","author":"Hoots","year":"2008","journal-title":"Haemophilia"},{"key":"2019111703153801700_B27","first-page":"30","article-title":"Immune tolerance for the treatment of factor VIII inhibitors--twenty years\u2019 \u2018bonn protocol\u2019","volume":"70","author":"Brackmann","year":"1996","journal-title":"Vox Sang"},{"issue":"4","key":"2019111703153801700_B28","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ajh.20204","article-title":"Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody","volume":"77","author":"Monahan","year":"2004","journal-title":"Am J Hematol"},{"issue":"4","key":"2019111703153801700_B29","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.1365-2516.2008.01953.x","article-title":"The application of bypassing-agent prophylaxis in haemophilia A patients with inhibitors: a meeting report","volume":"15","author":"Valentino","year":"2009","journal-title":"Haemophilia"},{"issue":"13","key":"2019111703153801700_B30","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood-2015-06-650226","article-title":"A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects","volume":"127","author":"Uchida","year":"2016","journal-title":"Blood"},{"key":"2019111703153801700_B31","article-title":"The potential of bispecific antibodies for treatment of hemophilia A [abstract]","volume":"13","author":"Shima","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2019111703153801700_B32","first-page":"59","article-title":"Thrombophilia as a multigenic disease","volume":"84","author":"Z\u00f6ller","year":"1999","journal-title":"Haematologica"},{"issue":"6","key":"2019111703153801700_B33","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.thromres.2014.02.014","article-title":"Clinical syndromes associated with acquired antithrombin deficiency via microvascular leakage and the related risk of thrombosis","volume":"133","author":"Ornaghi","year":"2014","journal-title":"Thromb Res"},{"issue":"6","key":"2019111703153801700_B34","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrd2310","article-title":"Interfering with disease: a progress report on siRNA-based therapeutics","volume":"6","author":"de Fougerolles","year":"2007","journal-title":"Nat Rev Drug Discov"},{"issue":"49","key":"2019111703153801700_B35","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J Am Chem Soc"},{"issue":"23","key":"2019111703153801700_B36","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1182\/blood.V126.23.551.551","article-title":"A subcutaneously administered investigational RNAi therapeutic (ALN-AT3) targeting antithrombin for treatment of hemophilia: interim weekly and monthly dosing results in patients with hemophilia A or B","volume":"126","author":"Pasi","year":"2015","journal-title":"Blood"},{"issue":"23","key":"2019111703153801700_B37","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood.V126.23.552.552","article-title":"Antithrombin reduction corrected thrombin generation in samples from hemophilia A and B patients with inhibitors","volume":"126","author":"Kenet","year":"2015","journal-title":"Blood"},{"issue":"24","key":"2019111703153801700_B38","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1182\/blood-2012-01-401620","article-title":"Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model","volume":"119","author":"Hilden","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2019111703153801700_B39","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jth.12864","article-title":"Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial","volume":"13","author":"Chowdary","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2019111703153801700_B40","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1538-7836.2012.04790.x","article-title":"Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma","volume":"10","author":"Gorczyca","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"21","key":"2019111703153801700_B41","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/blood.V120.21.2207.2207","article-title":"Effect of increased tissue factor pathway inhibitor (TFPI) levels on factor Xa inhibition and global hemostasis in the presence of TFPI-antagonistic aptamer BAX 499","volume":"120","author":"Dockal","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2019111703153801700_B42","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/jth.12477","article-title":"Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)","volume":"12","author":"Zollner","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2019111703153801700_B43","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1111\/jth.12409","article-title":"Safety and pharmacokinetics of a recombinant fusion protein linking coagulation factor VIIa with albumin in healthy volunteers","volume":"11","author":"Golor","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2019111703153801700_B44","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/jth.12237","article-title":"40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors","volume":"11","author":"Ljung","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"21","key":"2019111703153801700_B45","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood.V122.21.573.573","article-title":"The TRUST trial: anti-drug antibody formation in a patient with hemophilia with inhibitors after receiving the activated factor VII product Bay 86-6150","volume":"122","author":"Koh","year":"2013","journal-title":"Blood"},{"key":"2019111703153801700_B46","first-page":"143","article-title":"Acquired hemophilia A: emerging treatment options","volume":"6","author":"Janbain","year":"2015","journal-title":"J Blood Med"},{"key":"2019111703153801700_B47","article-title":"Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profile","author":"Lillicrap","year":"2015","journal-title":"Haemophilia"},{"issue":"5","key":"2019111703153801700_B48","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1365-2516.2012.02789.x","article-title":"Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A","volume":"18","author":"Kempton","year":"2012","journal-title":"Haemophilia"},{"issue":"11","key":"2019111703153801700_B49","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood.V110.11.783.783","article-title":"A phase II open-label study evaluating hemostatic activity, pharmacokinetics and safety of recombinant porcine factor VIII (OBI-1) in hemophilia A patients with alloantibody inhibitors directed against human FVIII","volume":"110","author":"Mahlangu","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2019111703153801700_B50","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/jth.12474","article-title":"Anti-factor IXa\/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation","volume":"12","author":"Muto","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2019111703153801700_B51","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Nat Med"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/657\/1249803\/hem088414.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/657\/1249803\/hem088414.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T08:16:15Z","timestamp":1573978575000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2016\/1\/657\/20988\/Hemophilia-and-inhibitors-current-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12,2]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2016.1.657","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,2]]}}}